The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by South African Health Products Regulatory Authority (SAHPRA) to proceed to Phase III human clinical study

1. Date of occurrence of the event: May 6, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. Reciprocal shareholding ratios: Not applicable 5. Cause of occurrence: The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by South African Health Products Regulatory […]